DIABETES:红酒护心，胖人不适用

　　多项实验发现，红葡萄酒中的抗氧化剂白藜芦醇，对改善胰岛素敏感度和心脏健康具有一定的功效。然而，《糖尿病》杂志刊登丹麦一项新研究发现，对肥胖男性而言，喝红酒对他们的血糖和心脏健康没有益处。

　　在丹麦奥尔胡斯大学附属医院科学家完成的这项新研究中，两组肥胖男性参试者连续4周分别每天服用1.5克白藜芦醇和安慰剂，结果发现，在胰岛素敏感度方面，两组无区别。在血压和血脂等心脏健康指标方面，两组参试者也无明显变化。

　　美国糖尿病协会会长维维安·冯塞卡博士解释称，适量饮用红酒的人可能生活方式更健康，因而寿命更长，胰岛素敏感度降低。然而，生活方式不健康的人补充白藜芦醇则不会改善胰岛素敏感度，无法达到降糖护心的目的。

Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and premature mortality. Based on animal and in vitro studies, resveratrol reverts these risk factors via stimulation of silent mating type information regulation 2 homolog 1 (SIRT1), but data in human subjects are scarce. The objective of this study was to examine the metabolic effects of high-dose resveratrol in obese human subjects. In a randomized, placebo-controlled, double-blinded, and parallel-group design, 24 obese but otherwise healthy men were randomly assigned to 4 weeks of resveratrol or placebo treatment. Extensive metabolic examinations including assessment of glucose turnover and insulin sensitivity (hyperinsulinemic euglycemic clamp) were performed before and after the treatment. Insulin sensitivity, the primary outcome measure, deteriorated insignificantly in both groups. Endogenous glucose production and the turnover and oxidation rates of glucose remained unchanged. Resveratrol supplementation also had no effect on blood pressure; resting energy expenditure; oxidation rates of lipid; ectopic or visceral fat content; or inflammatory and metabolic biomarkers. The lack of effect disagrees with persuasive data obtained from rodent models and raises doubt about the justification of resveratrol as a human nutritional supplement in metabolic disorders.